⁃ Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and provide written informed consent in accordance with institutional and regulatory guidelines

⁃ Age ≥ 18 years of age at the time of signing consent

⁃ Diagnosis of moderate to severe psoriasis of the genital area at Screening and baseline defined as modified sPGA-G score of ≥3.

⁃ Presence of non-genital plaque psoriasis (BSA ≥1%) at both Screening and Baseline.

⁃ Presence of psoriasis of the genital area that is inadequately controlled with topical therapy or the subject is intolerant to topical therapy

⁃ Negative evaluation for TB within 4 weeks before initiating IMP, defined as a negative QuantiFERON test. Subjects with a positive QuantiFERON test or 2 successive indeterminate

‣ QuantiFERON tests are allowed if they have all of the following:

• no history of active tuberculosis (TB) or symptoms of TB,

• a posteroanterior chest radiograph (with associated report available at the site) performed within 3 months of Screening with no evidence of active TB ( or of any other pulmonary infectious diseases),

• if prior latent TB infection, must have history of adequate prophylaxis (per local standard of care),

• if presence of latent TB is established, then treatment according to local country guidelines must have been followed for 4 weeks, prior to dosing in the study at Visit 2-Week 0.

‣ A maximum of 2 QuantiFERON tests of no more than 3 weeks apart are allowed. A re-test is only permitted if the first is indeterminate; the result of the second test will then be used